Drugs / EGFRt/19-28z/4-1BBL CAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03085173 | Mar 2017 → Mar 2027 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EGFRt/19-28z/4-1BBL CAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03085173 ↗ |
| Modality | Cell therapy | “modified T cells” NCT03085173 ↗ |
| Target | CD19 | “CD19-Targeted EGFRt/19-28z/4-1BBL” NCT03085173 ↗ |